CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models

2025/11/25 by Antonio Carlos Tallon-Cobos, Konstantinos Vazaios, Piotr Waranecki +11 · 1 voice
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #CAR-T cell therapy research #Immunotherapy and Immune Responses #Virus-based gene therapy research

paper · doi:10.1172/jci193332

openalex created_date 2025/11/25 · openalex publication_date 2025/11/25 · openalex updated_date 2026/07/22

Abstract

Aggressive pediatric brain tumor models of ependymoma are highly sensitive to GD2-directed (CAR T) cell therapy.

Discussions

• CAR T cells targeting the glycoprotein GD2 show potent antitumor efficacy in high-risk ependymoma models Antonio Carlos Tallon-Cobos & team present a new ependymoma model and demonstrate a promising [bsky, 1 points, 0 comments]

Related

• B7-H3 CAR T Cells Are Effective against Ependymomas but Limited by Tumor Size and Immune Response
• GD2-CAR T-cell Therapy is Safe in H3K27M+ Diffuse Midline Glioma
• A novel CAR T cell blend targeting PDPN and GD2 to overcome glioblastoma heterogeneity
• Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors
• Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b